Template:Dgfn2015 Mo 7:00 PCSK9

From HOP house of papers
Jump to: navigation, search

Contents

DGFN2015 Neue Wirkansätze in der Hyperlipidämie - Stellenwert für die Nephrologie (Rump-LC,Gouni-Berthold-I)

Session Videos

Lipidmanagement bei CKD-Patienten, Was ist belegt, was zu beachten. (Wanner-W)

Journal Paper, restricted access
GET A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Extract PDF direct
Journal Paper, restricted access
GET Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates Extract PDF direct
Journal Paper, restricted access
GET The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Extract PDF direct
Journal Paper, restricted access
GET Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Extract PDF direct

PCSK9-Inhibitoren: ein neuer Wirkmechanismus (Schettler-V)

Journal Paper, restricted access
GET A century of cholesterol and coronaries: from plaques to genes to statins Extract PDF direct
Journal Paper, restricted access
GET Targeting PCSK9 for hypercholesterolemia Extract PDF direct
Journal Paper, restricted access
GET The biology and therapeutic targeting of the proprotein convertases Extract PDF direct
Journal article, free access
GET Plasma membrane CD81 complexes with PCSK9 and LDLR and its levels are reduced by PCSK9 Extract PDF direct
Journal Paper, restricted access
GET Protease variants, LDL, and coronary heart disease Extract PDF direct
Journal article, free access
GET Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia Extract PDF direct
Journal Paper, restricted access
GET Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Extract PDF direct
Journal Paper, restricted access
GET Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis Extract PDF direct
Journal article, free access
GET Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease Extract PDF direct
Journal article, free access
GET Sequence variations in PCSK9, low LDL, and protection against coronary heart disease Extract PDF direct
Journal article, free access
GET Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study Extract PDF direct
Journal article, free access
GET The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol Extract PDF direct
Journal article, free access
GET The PCSK9 decade Extract PDF direct
Journal Paper, restricted access
GET Antihyperlipidemic therapies targeting PCSK9 Extract PDF direct
Journal Paper, restricted access
GET Pharmacotherapies for lipid modification: beyond the statins Extract PDF direct
Journal article, free access
GET Lipids and CVD management: towards a global consensus Extract PDF direct
Journal article, free access
GET High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol Extract PDF direct
Journal Paper, restricted access
GET The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe Extract PDF direct
Journal article, free access
GET A 52-week placebo-controlled trial of evolocumab in hyperlipidemia Extract PDF direct
Journal Paper, restricted access
GET Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Extract PDF direct
Journal article, free access
GET AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial Extract PDF direct
Journal Paper, restricted access
GET Lipoprotein(a) mass: a massively misunderstood metric Extract PDF direct
Journal article, free access (Hinweis: wrong paper ??? 2015;15:41 Schettler)
GET Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels Extract PDF direct
Journal article, free access
GET Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis Extract PDF direct

Was kommt nach den Statinen ? Aktuelles zu PCSK9 Antikörpern (König-W)

Journal article, free access
GET Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials Extract PDF direct
Journal Paper, restricted access
GET Meta-analysis of comparative efficacy of increas.ing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Extract PDF direct
Journal Paper, restricted access
GET Efficacy and safety of evolocumab in reducing lipids and cardiovascular events Extract PDF direct
Personal tools
Namespaces
Variants
Actions
Navigation
Toolbox
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis